Click here for slides on this topic


Glucose-dependent insulinotropic polypeptide (GIP)

The gastrointestinal hormone gastric inhibitory polypeptide is released from the gut after a meal and stimulates insulin secretion.


The following content matched the glossary term: Glucose-dependent insulinotropic polypeptide (GIP)

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes

Top

D'Alessio DA, Denney AM, Hermiller LM, et al. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.J Clin Endocrinol Metab. 2009;94(1):81-88. Dipeptidyl peptidase 4 (DPP-4) inhibitors are proposed to lower blood glucose in type 2 diabetes mellitus (T2DM) by prolonging the activity of the circulating incretins, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1).

Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes

Top

McGill JB. Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes. Postgrad Med. 2009;121(1):46-58. Glucose homeostasis is governed by a complex interplay of hormonal signaling and modulation. Insulin, glucagon, amylin, the incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), and other hormones and enzymes interact to maintain glucose homeostasis and normal cellular metabolism. 

The incretins: From the concept to their use in the treatment of type 2 diabetes. Part A: Incretins: Concept and physiologic functions

Top

Girard J. The incretins: From the concept to their use in the treatment of type 2 diabetes. Part A: Incretins: Concept and physiologic functions. Diabetes Metab. 2008;34(6):550-559. This paper briefly reviews the concept of incretins and describes the biological effects of the two incretins identified so far: the glucose-dependent insulinotropic polypeptide (GIP); and the glucagon-like peptide-1 (GLP-1). GIP is released by the Kcells of the duodenum, while GLP-1 is released by the Lcells of the distal ileum, in response to nutrient absorption.

Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes

Top

Gupta R, Walunj SS, Tokala RK, Parsa KV, Singh SK, Pal M. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of type 2 diabetes. Curr Drug Targets. 2009;10(1):71-87. Dipeptidyl peptidase IV (DPP IV) is a key regulator of insulin-stimulating hormones, glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thus it is a promising target for the treatment of Type 2 Diabetes mellitus (T2DM).

Vildagliptin: a review of its use in the management of type 2 diabetes mellitus

Top

Croxtall JD, Keam SJ. Vildagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2008;68(16):2387-2409. Vildagliptin (Galvus®) is an antihyperglycaemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. Such inhibition prevents the degradation of the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).

Treatment with the DPP-4 inhibitor Vildagliptin improves fasting islet-cell function in subjects with Type 2 diabetes

Top

D'Alessio, DA, Denney AM, Hermiller LM, et al. Treatment with the DPP-4 inhibitor Vildagliptin improves fasting islet-cell function in subjects with Type 2 diabetes. J Clin Endocrinol Metab. 2008;epub ahead of print. Dipeptidyl peptidase 4 (DPP-4) inhibitors are proposed to lower blood glucose in type 2 diabetes (T2DM) by prolonging the activity of the circulating incretins, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1).



Slide Library Results

Search Results for: Glucose-dependent insulinotropic polypeptide (GIP) Slides Found: 0